700 related articles for article (PubMed ID: 35132063)
1. Emerging new therapeutic antibody derivatives for cancer treatment.
Jin S; Sun Y; Liang X; Gu X; Ning J; Xu Y; Chen S; Pan L
Signal Transduct Target Ther; 2022 Feb; 7(1):39. PubMed ID: 35132063
[TBL] [Abstract][Full Text] [Related]
2. Bispecific Antibodies and Antibody-Drug Conjugates for Cancer Therapy: Technological Considerations.
Shim H
Biomolecules; 2020 Feb; 10(3):. PubMed ID: 32111076
[TBL] [Abstract][Full Text] [Related]
3. Antibody treatment in multiple myeloma.
Maples KT; Johnson C; Lonial S
Clin Adv Hematol Oncol; 2021 Mar; 19(3):166-174. PubMed ID: 33739965
[TBL] [Abstract][Full Text] [Related]
4. Bringing Together the Power of T Cell Receptor Mimic and Bispecific Antibodies for Cancer Immunotherapy: Still a Long Way to Go.
Shivarov V; Blazhev G
Monoclon Antib Immunodiagn Immunother; 2021 Apr; 40(2):81-85. PubMed ID: 33900820
[TBL] [Abstract][Full Text] [Related]
5. Principles and Current Clinical Landscape of Multispecific Antibodies against Cancer.
Elshiaty M; Schindler H; Christopoulos P
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073188
[TBL] [Abstract][Full Text] [Related]
6. Bispecific Antibody (bsAb) Construct Formats and their Application in Cancer Therapy.
Acheampong DO
Protein Pept Lett; 2019; 26(7):479-493. PubMed ID: 30864494
[TBL] [Abstract][Full Text] [Related]
7. Cancer therapy with antibodies.
Paul S; Konig MF; Pardoll DM; Bettegowda C; Papadopoulos N; Wright KM; Gabelli SB; Ho M; van Elsas A; Zhou S
Nat Rev Cancer; 2024 Jun; 24(6):399-426. PubMed ID: 38740967
[TBL] [Abstract][Full Text] [Related]
8. Precision medicine in clinical oncology: the journey from IgG antibody to IgE.
Fazekas-Singer J; Singer J; Jensen-Jarolim E
Curr Opin Allergy Clin Immunol; 2020 Jun; 20(3):282-289. PubMed ID: 32349107
[TBL] [Abstract][Full Text] [Related]
9. Bispecific antibody based therapeutics: Strengths and challenges.
Thakur A; Huang M; Lum LG
Blood Rev; 2018 Jul; 32(4):339-347. PubMed ID: 29482895
[TBL] [Abstract][Full Text] [Related]
10. Immunocytokines and bispecific antibodies: two complementary strategies for the selective activation of immune cells at the tumor site.
Kiefer JD; Neri D
Immunol Rev; 2016 Mar; 270(1):178-92. PubMed ID: 26864112
[TBL] [Abstract][Full Text] [Related]
11. Improved cancer therapy and molecular imaging with multivalent, multispecific antibodies.
Sharkey RM; Rossi EA; Chang CH; Goldenberg DM
Cancer Biother Radiopharm; 2010 Feb; 25(1):1-12. PubMed ID: 20187791
[TBL] [Abstract][Full Text] [Related]
12. Advances in Antibody-Drug Conjugate Design: Current Clinical Landscape and Future Innovations.
Gauzy-Lazo L; Sassoon I; Brun MP
SLAS Discov; 2020 Sep; 25(8):843-868. PubMed ID: 32192384
[TBL] [Abstract][Full Text] [Related]
13. Monoclonal Antibodies, Bispecific Antibodies and Antibody-Drug Conjugates in Oncohematology.
Mihăilă RG
Recent Pat Anticancer Drug Discov; 2020; 15(4):272-292. PubMed ID: 32981510
[TBL] [Abstract][Full Text] [Related]
14. CD123 bi-specific antibodies in development in AML: What do we know so far?
Slade MJ; Uy GL
Best Pract Res Clin Haematol; 2020 Dec; 33(4):101219. PubMed ID: 33279175
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: Part 1, monoclonal antibodies, antibody-drug conjugates and bispecific T-cell engagers.
Paci A; Desnoyer A; Delahousse J; Blondel L; Maritaz C; Chaput N; Mir O; Broutin S
Eur J Cancer; 2020 Mar; 128():107-118. PubMed ID: 32037061
[TBL] [Abstract][Full Text] [Related]
16. Bispecific monoclonal antibodies for targeted immunotherapy of solid tumors: Recent advances and clinical trials.
Hosseini SS; Khalili S; Baradaran B; Bidar N; Shahbazi MA; Mosafer J; Hashemzaei M; Mokhtarzadeh A; Hamblin MR
Int J Biol Macromol; 2021 Jan; 167():1030-1047. PubMed ID: 33197478
[TBL] [Abstract][Full Text] [Related]
17. Next generation antibody drugs: pursuit of the 'high-hanging fruit'.
Carter PJ; Lazar GA
Nat Rev Drug Discov; 2018 Mar; 17(3):197-223. PubMed ID: 29192287
[TBL] [Abstract][Full Text] [Related]
18. Coming-of-Age of Antibodies in Cancer Therapeutics.
Ayyar BV; Arora S; O'Kennedy R
Trends Pharmacol Sci; 2016 Dec; 37(12):1009-1028. PubMed ID: 27745709
[TBL] [Abstract][Full Text] [Related]
19. Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond.
Su CT; Ye JC
J Hematol Oncol; 2021 Jul; 14(1):115. PubMed ID: 34301270
[TBL] [Abstract][Full Text] [Related]
20. Current landscape and future directions of bispecific antibodies in cancer immunotherapy.
Wei J; Yang Y; Wang G; Liu M
Front Immunol; 2022; 13():1035276. PubMed ID: 36389699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
